Search Results
Some patients with TED need longer to respond to teprotumumab
Patients with thyroid eye disease (TED) treated with teprotumumab may need longer than 12 weeks to see a clinically significant...
Read MoreTED Google searches increased 525% after teprotumumab commercial
Direct-to-consumer advertising may have helped to increase public interest for thyroid eye disease (TED), according to researchers who noted an...
Read MoreMore studies needed on hearing loss linked to teprotumumab use in TED
Due to the potential for hearing loss in patients treated with teprotumumab for thyroid eye disease (TED), baseline audiometry and...
Read MoreAnalysis compares teprotumumab vs intravenous methylprednisolone vs placebo in TED
Results from a meta-analysis suggest that the use of intravenous methylprednisolone (IVMP) in patients with thyroid eye disease (TED) may...
Read MoreStudy examines success of lateral orbital wall decompression in pediatric TED
A lateral orbital decompression via a conjunctival incision over the lateral orbital rim without a canthotomy or cantholysis can be...
Read MoreBaseline imaging may predict teprotumumab response
Total rectus volume is predictive of proptosis reduction following treatment with teprotumumab in patients with thyroid eye disease (TED), according...
Read MoreTED may result in changes across the entire face
A study found that the effects thyroid eye disease (TED) has on soft tissue may expand beyond the orbit and...
Read MoreCoupled medical and surgical treatment needed for TED
Despite the session topic focusing on surgery for patients with inactive thyroid eye disease (TED), Louis A Mawn, MD, Professor...
Read MorePOLL: Do you believe all TED is inflammatory/active?
During a presentation at AAO 2021 Subspecialty Day, Louis A Mawn, MD, discussed Rundle's curve, a term often used in Graves ophthalmopathy...
Read MoreTeprotumumab is a ‘powerful resource’ for ophthalmologists treating TED
During a presentation at AAO Subspecialty Day 2021, Suzanne K. Freitag, MD, Director of the Ophthalmic Plastic Surgery Service at...
Read MoreRecalcitrant TED responsive to teprotumumab
Patients with recalcitrant thyroid eye disease (TED) treated with teprotumumab demonstrated a significant improvement in clinical activity score (CAS), proptosis...
Read MoreCase Series: TED reactivation after COVID-19 vaccination
Due to the potential risk of autoimmune disease reactivation after COVID-19 vaccination noted by the American College of Rheumatology, researchers...
Read MoreTeprotumumab adherence rates are high in patients with TED
Patients with thyroid eye disease (TED) appear to adhere to treatment with teprotumumab in clinical practice like controlled trial findings,...
Read More